Lessons Learned from Two Decades of Anticancer Drugs

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Anticancer drug development has evolved significantly over 20 years, shifting from cytotoxic agents to targeted and immune-based therapies.
• Over 200 anticancer drugs are now available, yet development remains high-risk with significant attrition in later clinical trial phases.

Purpose of the Study:

• To review successful and unsuccessful anticancer drug development experiences from the past two decades.
• To identify limitations in the current drug development paradigm.
• To propose strategies for enhancing the success rate of anticancer drug candidates.

Main Methods:

• Review of historical data on anticancer drug development.
• Analysis of attrition rates and reasons for failure in clinical trials.
• Synthesis of successful and failed case studies.

Main Results:

• Shortcomings in translating preclinical findings (in vitro and in vivo) to human patients contribute to high failure rates.
• Patient population heterogeneity poses a significant challenge in anticancer drug development.
• Current drug development paradigms may be suboptimal in addressing these translational and heterogeneity issues.

Conclusions:

• Despite advancements, anticancer drug development remains challenging due to translational gaps and patient variability.
• A critical evaluation of past development experiences is necessary to refine current strategies.
• Implementing improved strategies is crucial for increasing the success of future anticancer drug discovery and development.